MK-8583

MK-8583 · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-8583, covering 2020-03-04 to 2020-03-04. Get the full timeline:

Most recent: Clinical Trial Update: MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002) [Phase 1]

See pricing